GrippeCanadaV4, Main, Exploration, bibRecordById, pubmed:29912696

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Identifieur interne : 000050 ( Main/Exploration ); précédent : 000049; suivant : 000051

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Auteurs : Salaheddin M. Mahmud ; Songul Bozat-Emre ; Luiz C. Mostaço-Guidolin ; Ruth Ann Marrie

Source :

Emerging infectious diseases [ 1080-6059 ] ; 2018.

RBID : pubmed:29912696

Descripteurs français

KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Appréciation des risques (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Enregistrements (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Incidence (MeSH), Jeune adulte (MeSH), Manitoba (épidémiologie), Mâle (MeSH), Nourrisson (MeSH), Sclérose en plaques (épidémiologie), Sclérose en plaques (étiologie), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Surveillance de la population (MeSH), Vaccins antigrippaux (effets indésirables).
MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A.
- épidémiologie : Manitoba, Sclérose en plaques.
- étiologie : Sclérose en plaques.
- Adolescent, Adulte, Adulte d'âge moyen, Appréciation des risques, Enfant, Enfant d'âge préscolaire, Enregistrements, Facteurs de risque, Femelle, Humains, Incidence, Jeune adulte, Mâle, Nourrisson, Sujet âgé, Surveillance de la population.

English descriptors

KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Humans (MeSH), Incidence (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (adverse effects), Male (MeSH), Manitoba (epidemiology), Middle Aged (MeSH), Multiple Sclerosis (epidemiology), Multiple Sclerosis (etiology), Population Surveillance (MeSH), Registries (MeSH), Risk Assessment (MeSH), Risk Factors (MeSH), Young Adult (MeSH).
MESH :
- chemical , adverse effects : Influenza Vaccines.
- geographic , epidemiology : Manitoba.
- epidemiology : Multiple Sclerosis.
- etiology : Multiple Sclerosis.
- immunology : Influenza A Virus, H1N1 Subtype.
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Incidence, Infant, Male, Middle Aged, Population Surveillance, Registries, Risk Assessment, Risk Factors, Young Adult.

Abstract

To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, and prescription drug claims databases. After 12 months of follow-up, the age-adjusted incidence rate of MS was 17.7 cases per 100,000 person-years in the Arepanrix cohort and 24.2 per 100,000 in the unvaccinated cohort. The corresponding adjusted hazard ratio was 0.9. We observed similar patterns when we measured incidence over the entire follow-up period. The AS03 adjuvant, a candidate for inclusion in future pandemic vaccines, does not appear to increase the short-term risk for MS when included in influenza vaccines.

DOI: 10.3201/eid2407.161783
PubMed: 29912696
PubMed Central: PMC6038732

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000049
to stream Main, to step Curation: 000049

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.</title>
<author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
</author>
<author><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name>
</author>
<author><name sortKey="Mostaco Guidolin, Luiz C" sort="Mostaco Guidolin, Luiz C" uniqKey="Mostaco Guidolin L" first="Luiz C" last="Mostaço-Guidolin">Luiz C. Mostaço-Guidolin</name>
</author>
<author><name sortKey="Marrie, Ruth Ann" sort="Marrie, Ruth Ann" uniqKey="Marrie R" first="Ruth Ann" last="Marrie">Ruth Ann Marrie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:29912696</idno>
<idno type="pmid">29912696</idno>
<idno type="doi">10.3201/eid2407.161783</idno>
<idno type="pmc">PMC6038732</idno>
<idno type="wicri:Area/Main/Corpus">000049</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000049</idno>
<idno type="wicri:Area/Main/Curation">000049</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000049</idno>
<idno type="wicri:Area/Main/Exploration">000049</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.</title>
<author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
</author>
<author><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name>
</author>
<author><name sortKey="Mostaco Guidolin, Luiz C" sort="Mostaco Guidolin, Luiz C" uniqKey="Mostaco Guidolin L" first="Luiz C" last="Mostaço-Guidolin">Luiz C. Mostaço-Guidolin</name>
</author>
<author><name sortKey="Marrie, Ruth Ann" sort="Marrie, Ruth Ann" uniqKey="Marrie R" first="Ruth Ann" last="Marrie">Ruth Ann Marrie</name>
</author>
</analytic>
<series><title level="j">Emerging infectious diseases</title>
<idno type="eISSN">1080-6059</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Male (MeSH)</term>
<term>Manitoba (epidemiology)</term>
<term>Middle Aged (MeSH)</term>
<term>Multiple Sclerosis (epidemiology)</term>
<term>Multiple Sclerosis (etiology)</term>
<term>Population Surveillance (MeSH)</term>
<term>Registries (MeSH)</term>
<term>Risk Assessment (MeSH)</term>
<term>Risk Factors (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Appréciation des risques (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Enregistrements (MeSH)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Manitoba (épidémiologie)</term>
<term>Mâle (MeSH)</term>
<term>Nourrisson (MeSH)</term>
<term>Sclérose en plaques (épidémiologie)</term>
<term>Sclérose en plaques (étiologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sujet âgé (MeSH)</term>
<term>Surveillance de la population (MeSH)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Manitoba</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Multiple Sclerosis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Multiple Sclerosis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Manitoba</term>
<term>Sclérose en plaques</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Sclérose en plaques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Population Surveillance</term>
<term>Registries</term>
<term>Risk Assessment</term>
<term>Risk Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Appréciation des risques</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Enregistrements</term>
<term>Facteurs de risque</term>
<term>Femelle</term>
<term>Humains</term>
<term>Incidence</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Sujet âgé</term>
<term>Surveillance de la population</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, and prescription drug claims databases. After 12 months of follow-up, the age-adjusted incidence rate of MS was 17.7 cases per 100,000 person-years in the Arepanrix cohort and 24.2 per 100,000 in the unvaccinated cohort. The corresponding adjusted hazard ratio was 0.9. We observed similar patterns when we measured incidence over the entire follow-up period. The AS03 adjuvant, a candidate for inclusion in future pandemic vaccines, does not appear to increase the short-term risk for MS when included in influenza vaccines.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29912696</PMID>
<DateCompleted><Year>2019</Year>
<Month>04</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>04</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1080-6059</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>7</Issue>
<PubDate><Year>2018</Year>
<Month>07</Month>
</PubDate>
</JournalIssue>
<Title>Emerging infectious diseases</Title>
<ISOAbbreviation>Emerging Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.</ArticleTitle>
<Pagination><MedlinePgn>1267-1274</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3201/eid2407.161783</ELocationID>
<Abstract><AbstractText>To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, and prescription drug claims databases. After 12 months of follow-up, the age-adjusted incidence rate of MS was 17.7 cases per 100,000 person-years in the Arepanrix cohort and 24.2 per 100,000 in the unvaccinated cohort. The corresponding adjusted hazard ratio was 0.9. We observed similar patterns when we measured incidence over the entire follow-up period. The AS03 adjuvant, a candidate for inclusion in future pandemic vaccines, does not appear to increase the short-term risk for MS when included in influenza vaccines.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmud</LastName>
<ForeName>Salaheddin M</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bozat-Emre</LastName>
<ForeName>Songul</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mostaço-Guidolin</LastName>
<ForeName>Luiz C</ForeName>
<Initials>LC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marrie</LastName>
<ForeName>Ruth Ann</ForeName>
<Initials>RA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Emerg Infect Dis</MedlineTA>
<NlmUniqueID>9508155</NlmUniqueID>
<ISSNLinking>1080-6040</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C568072">arepanrix</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N" Type="Geographic">Manitoba</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Adjuvant</Keyword>
<Keyword MajorTopicYN="Y">Arepanix</Keyword>
<Keyword MajorTopicYN="Y">Canada</Keyword>
<Keyword MajorTopicYN="Y">Multiple sclerosis</Keyword>
<Keyword MajorTopicYN="Y">cohort studies</Keyword>
<Keyword MajorTopicYN="Y">influenza</Keyword>
<Keyword MajorTopicYN="Y">pandemic influenza vaccine</Keyword>
<Keyword MajorTopicYN="Y">risk</Keyword>
<Keyword MajorTopicYN="Y">vaccination</Keyword>
<Keyword MajorTopicYN="Y">vaccines</Keyword>
<Keyword MajorTopicYN="Y">viruses</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>6</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>4</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">29912696</ArticleId>
<ArticleId IdType="doi">10.3201/eid2407.161783</ArticleId>
<ArticleId IdType="pmc">PMC6038732</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Neuroepidemiology. 1994;13(1-2):1-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8190200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Intern Med. 2014 Feb;275(2):172-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24134219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Neurol. 2013 Sep 26;13:128</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24070256</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Public Health. 1994 Oct;84(10):1666-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7943493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2011 Sep;5(5):299-305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21668694</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Oct 26;29(46):8302-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21893148</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Nov 19;30(49):7123-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23022149</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol. 2011 Aug;258(8):1545-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21336784</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Neurol. 1996 Dec;53(12):1216</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8970447</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2014 Dec;71(12):1506-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25329096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chronic Dis Inj Can. 2014 Jul;34(2-3):145-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24991777</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2011 Oct 12;343:d5956</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21994316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Pharmacother. 1998 Nov;32(11):1152-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9825079</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuroepidemiology. 1994;13(3):120-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8015665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Neurol. 1978 Apr;35(4):242-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">637761</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autoimmun Rev. 2013 Aug;12(10):990-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23541483</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuroepidemiology. 1990;9(5):248-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2087249</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Care. 1998 Jan;36(1):8-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9431328</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2011 Oct 19;29(45):7975-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21884747</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1997 Oct 15;127(8 Pt 2):757-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9382394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2001 Feb 1;344(5):319-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11172162</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Neurol. 2004 Dec;3(12):709-18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15556803</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2012 Dec 18;345:e7594</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23274350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mult Scler. 2012 Feb;18(2):254-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21828198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S546-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">342627</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurol Sci. 2003 Nov;24(4):242-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14658040</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiology. 2009 Jul;20(4):512-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19487948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Care. 1993 Mar;31(3):201-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8450678</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 2005 Oct 11;65(7):1066-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16217060</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurol. 2011 Jul;258(7):1197-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21431896</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):749-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15386720</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 2002 Dec 24;59(12):1837-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12499473</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(9):e24384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21915319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Rev. 2003;25:43-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12923989</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 2010 Feb 9;74(6):465-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20071664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neuroepidemiology. 2013;40(3):195-210</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23363936</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2012 Jul;8(7):851-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22777099</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name>
<name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name>
<name sortKey="Marrie, Ruth Ann" sort="Marrie, Ruth Ann" uniqKey="Marrie R" first="Ruth Ann" last="Marrie">Ruth Ann Marrie</name>
<name sortKey="Mostaco Guidolin, Luiz C" sort="Mostaco Guidolin, Luiz C" uniqKey="Mostaco Guidolin L" first="Luiz C" last="Mostaço-Guidolin">Luiz C. Mostaço-Guidolin</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000050 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000050 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeCanadaV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:29912696
   |texte=   Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:29912696" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV4

This area was generated with Dilib version V0.6.35.
Data generation: Sat Aug 8 18:52:12 2020. Site generation: Sat Feb 13 16:40:04 2021

	Serveur d'exploration sur la grippe au Canada
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe au Canada

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki